← Back to patent-cliff list

Guadecitabine Sodium

Tier C — Watch / trade

Guadecitabine Sodium

Otsuka Holdings Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:DNMT1

Indications (approved):软骨肉瘤, Non-small cell lung cancer, Melanoma, Small cell lung cancer, Urothelial carcinoma, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer

Regional status

US
Phase II
2011-01-04
EU
Phase II
2012-09-01
China
-
Japan
No progress
2015-03-19

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 9 · Total yield /
GUAD-0012353-33-5GUAD-002431890-05-0GUAD-00314316-61-1GUAD-004929904-94-9GUAD-005929904-95-0GUAD-006—GUAD-007102691-36-1GUAD-008—GUAD-009—GUAD-010—GUAD-011—GUAD-012—API · Guadecitabine Sodium
CodeCAS No.Intermediate
GUAD-0012353-33-54-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
GUAD-002431890-05-04-amino-1-((2R,4S,5R)-4-((trimethylsilyl)oxy)-5-(((trimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
GUAD-00314316-61-12-phenoxyacetic anhydride
GUAD-004929904-94-9N-(4-oxo-5-((2R,4S,5R)-4-((trimethylsilyl)oxy)-5-(((trimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-4,5-dihydro-1,3,5-triazin-2-yl)-2-phenoxyacetamide
GUAD-005929904-95-0N-(5-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,5-dihydro-1,3,5-triazin-2-yl)-2-phenoxyacetamide
GUAD-006--
GUAD-007102691-36-13-((bis(diisopropylamino)phosphaneyl)oxy)propanenitrile
GUAD-008--
GUAD-009--
GUAD-010--
GUAD-011--
GUAD-012--

Frequently asked questions

What are the approved indications of Guadecitabine Sodium?

Approved indications include: 软骨肉瘤, Non-small cell lung cancer, Melanoma, Small cell lung cancer, Urothelial carcinoma, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer.

When does the Guadecitabine Sodium patent expire?

No public expiry year is available for Guadecitabine Sodium yet; this page updates once verified.

How many synthesis routes are recorded for Guadecitabine Sodium?

1 synthesis routes are recorded; the shortest is 9 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Guadecitabine Sodium intermediates?

All intermediates in Guadecitabine Sodium routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Guadecitabine Sodium intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-19